<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819647</url>
  </required_header>
  <id_info>
    <org_study_id>HYPOP (STP194)</org_study_id>
    <nct_id>NCT03819647</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria</brief_title>
  <official_title>Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocodex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of stiripentol (Diacomit) as monotherapy for the treatment of
      primary hyperoxaluria.

      Pilot clinical study, open, prospective and multicenter.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after two weeks of treatment.</measure>
    <time_frame>Change (%) of the molar ratio [oxaluria / creatinuria] between the baseline value (average of 3 measures done during pre-treatment period) and the value (average of 2 measures) after 2 weeks of treatment.</time_frame>
    <description>Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after two weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after three weeks of treatment.</measure>
    <time_frame>Change (%) of the molar ratio [oxaluria / creatinuria] between the baseline value (average of 3 measures done during pre-treatment period) and the value (average of 2 measures) after 3 weeks of treatment.</time_frame>
    <description>Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after three weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment defined by a decrease&gt; 20% of the molar ratio [oxaluria / creatinuria]</measure>
    <time_frame>3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)</time_frame>
    <description>Response to treatment defined by a decrease&gt; 20% of the molar ratio [oxaluria / creatinuria]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative variation (%) of supersaturation of urine with calcium oxalate between the start and the end of treatment period</measure>
    <time_frame>3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)</time_frame>
    <description>Relative variation (%) of supersaturation of urine with calcium oxalate between the start and the end of treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative variation (%) in overall crystalline volume measured by crystalluria on fresh urine between the start and the end of treatment period</measure>
    <time_frame>3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)</time_frame>
    <description>Relative variation (%) in overall crystalline volume measured by crystalluria on fresh urine between the start and the end of treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of stiripentol dose increase on absolute decrease of the molar ratio [oxaluria / creatinuria]</measure>
    <time_frame>3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)</time_frame>
    <description>Effect of stiripentol dose increase on absolute decrease of the molar ratio [oxaluria / creatinuria]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of stiripentol dose increase on relative decrease (%) of the molar ratio [oxaluria / creatinuria]</measure>
    <time_frame>3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)</time_frame>
    <description>Effect of stiripentol dose increase on relative decrease (%) of the molar ratio [oxaluria / creatinuria]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test results (hepatic assessment) at the start and at the end of the study</measure>
    <time_frame>From start of participation of the patient to end of the treatment period (up to 8 weeks)</time_frame>
    <description>Blood test results (hepatic assessment) at the start and at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test results (blood cells count) at the start and at the end of the study</measure>
    <time_frame>From start of participation of the patient to end of the treatment period (up to 8 weeks)</time_frame>
    <description>Blood test results (blood cells count) at the start and at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and nature of the adverse events throughout the study</measure>
    <time_frame>From start of participation of the patient to end of the treatment period (up to 8 weeks)</time_frame>
    <description>Frequency and nature of the adverse events throughout the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>stiripentol (Diacomit)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stiripentol (Diacomit)</intervention_name>
    <description>Administration of stiripentol per os</description>
    <arm_group_label>stiripentol (Diacomit)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with primary hyperoxaluria type 1, 2 or 3, diagnosed according to standard
             methods

          -  Having at least one molar ratio [oxaluria / creatinuria] greater than 0.08 since
             diagnosis

          -  Having Glomerular Filtration Rate ≥ 45 mL / min / 1.73m2

          -  Age ≥ 6 months

          -  Having read, or whose parents have read, the information note and signed the consent
             form. For children, if their level of understanding allows, their assent will also be
             sought

          -  Proficient enough, or whose parents or legal representatives have sufficient mastery,
             the French language to read, understand and complete study documents

          -  Affiliate or beneficiary of a social security scheme

          -  Ability to respect the protocol, including treatment, and can be followed regularly in
             the study

          -  For pubertal patients, contraception deemed effective by the investigator or
             abstinence

        Exclusion Criteria:

          -  Introduction, discontinuation or dose modification of vitamin B6 or potassium citrate
             treatment within 4 weeks prior to the inclusion visit

          -  Consumption of jelly candies and / or dark chocolate in the week preceding the study

          -  Patient having a kidney and / or liver transplant

          -  Presence of a clinically significant acute or chronic pathology, other than primary
             hyperoxaluria, that may interfere with the evaluation of the study results according
             to the investigator

          -  During biological or physical examinations, presence of significant anomaly (s)
             inconsistent with participation in the study according to the investigator

          -  History of severe allergy, asthma, skin rash or hypersensitivity to a drug

          -  Treatment affecting hepatic metabolism (cimetidine, ketoconazole, fluconazole,
             itraconazole, phenytoin, rifampicin, rifabutin) in progress or taken during the month
             preceding the start of the study

          -  Treatment affecting the renal tubule (probenecid, β-lactams, ...) in progress or taken
             during the last two weeks preceding the start of the study

          -  Presence of a pathology or treatment that, according to the investigator, renders the
             subject unfit

          -  Contraindications to stiripentol as defined in the current SmPC (hypersensitivity to
             the active substance or to any of the excipients listed in section 6.1 of the SmPC,
             history of psychosis in the form of delusional episodes)

          -  Pregnant or lactating woman

          -  Patient under guardianship

          -  Patient concurrently participating in another clinical trial or exclusion period
             following a previous trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stiripentol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

